BRCA1: A new genomic marker for non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue 6, 2008, Pages 331-339

  Reguart, Noemi ^a,d   Cardona, Andres Felipe ^a,b   Carrasco, Esther ^a   Gomez, Patricia ^a,c   Taron, Miquel ^a   Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

^c Medical Oncology   (Argentina)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Angiopoietins; Predictive prognositc factors; Topoisomerase poisons; Ubiquitination

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MOLECULAR MARKER; NAVELBINE; PACLITAXEL;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CHROMATIN STRUCTURE; CHROMOSOME 17Q; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE MARKER; DNA STRAND BREAKAGE; GENE LOCATION; HUMAN; LUNG NON SMALL CELL CANCER; MARKER GENE; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SURVIVAL TIME; UBIQUITINATION; X CHROMOSOME INACTIVATION;

EID: 59449097300     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.048     Document Type: Review

References (105)

1. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-9.
2. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
3. Mullan PB, Gorski JJ, Harkin DP. BRCA1-a good predictive marker of drug sensitivity in breast cancer treatment? Biochim Biophys Acta 2006; 1766:205-16.
4. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63:6221-8.
5. Kennedy RD, Quinn JE, Johnston PG, et al. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002; 360:1007-14.
6. Delbaldo C, Michiels S, Rolland E, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007; (4):CD004569.
7. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13:2443-9.
8. Smith TM, Lee MK, Szabo CI, et al. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 1996; 6:1029-49.
9. Chen Y, Farmer AA, Chen CF, et al. BRCA1 is a 220-kDa nuclear phospho-protein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996; 56:3168-72.
10. Hashizume R, Fukuda M, Maeda I, et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 2001; 276:14537-40.
11. Wang Y, Cortez D, Yazdi P, et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000; 14:927-39.
12. Li S, Chen PL, Subramanian T, et al. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem 1999; 274:11334-8.
13. Zheng L, Pan H, Li S, et al. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 2000; 6:757-68.
14. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96:1659-68.
15. Marquis ST, Rajan JV, Wynshaw-Boris A, et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995; 11:17-26.
16. Furuta S, Wang JM, Wei S, et al. Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell 2006; 10:13-24.
17. Li S, Ting NS, Zheng L, et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 2000; 406:210-5.
18. Yu X, Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 2004; 24:9478-86.
19. Chinnadurai G. CtIP, a candidate tumor susceptibility gene is a team player with luminaries. Biochim Biophys Acta 2006; 1765:67-73.
20. Scully R, Anderson SF, Chao DM, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997; 94:5605-10.
21. Chiba N, Parvin JD. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. Cancer Res 2002; 62:4222-8.
22. Anderson SF, Schlegel BP, Nakajima T, et al. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 1998; 19:254-6.
23. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 2003; 15:345-50.
24. MacLachlan TK, Somasundaram K, Sgagias M, et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 2000; 275:2777-85.
25. MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53-de- pendent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 2002; 22:4280-92.
26. Yarden RI, Pardo-Reoyo S, Sgagias M, et al. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002; 30:285-9.
27. Wang Q, Zhang H, Kajino K, et al. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 1998; 17:1939-48.
28. Kennedy RD, Gorski JJ, Quinn JE, et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 2005; 65:10265-72.
29. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008; 18:134-47.
30. Le Page F, Randrianarison V, Marot D, et al. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000; 60:5548-52.
31. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411:366-74.
32. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000; 10:144-50.
33. Zhong Q, Chen CF, Chen PL, et al. BRCA1 facilitates microhomology- mediated end joining of DNA double strand breaks. J Biol Chem 2002; 277:28641-7.
34. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000; 275:33487-96.
35. Hsu LC, White RL. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci U S A 1998; 95:12983-8.
36. Morris JR, Pangon L, Boutell C, et al. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet 2006; 15:599-606.
37. Kentsis A, Gordon RE, Borden KL. Self-assembly properties of a model RING domain. Proc Natl Acad Sci U S A 2002; 99:667-72.
38. Starita LM, Parvin JD. Substrates of the BRCA1-dependent ubiquitin ligase. Cancer Biol Ther 2006; 5:137-41.
39. Neish AS, Anderson SF, Schlegel BP, et al. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucleic Acids Res 1998; 26:847-53.
40. Bochar DA, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000; 102:257-65.
41. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacety-lase complex. Proc Natl Acad Sci U S A 1999; 96:4983-8.
42. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59.
43. Ye Q, Hu YF, Zhong H, et al. BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J Cell Biol 2001; 155:911-21.
44. Ganesan S, Silver DP, Greenberg RA, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 2002; 111:393-405.
45. Caine GJ, Blann AD, Stonelake PS, et al. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 2003; 33:883-90.
46. Machein MR, Knedla A, Knoth R, et al. Angiopoietin-1 promotes tumor angio- genesis in a rat glioma model. Am J Pathol 2004; 165:1557-70.
47. Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000; 102:199-209.
48. Wong MP, Chan SY, Fu KH, et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 2000; 29:11-22.
49. Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002; 62:7124-9.
50. Mah V, Seligson DB, Li A, et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 2007; 67:10484-90.
51. Fedier A, Steiner RA, Schwarz VA, et al. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003; 22:1169-73.
52. Husain A, He G, Venkatraman ES, et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998; 58:1120-3.
53. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002; 20:845-53.
54. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
55. Ruffner H, Joazeiro CA, Hemmati D, et al. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A 2001; 98:5134-9.
56. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266:120-2.
57. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-6.
58. Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20:6123-31.
59. Ouchi T, Monteiro AN, August A, et al. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 1998; 95:2302-6.
60. Houvras Y, Benezra M, Zhang H, et al. BRCA1 physically and functionally interacts with ATF1. J Biol Chem 2000; 275:36230-7.
61. Li H, Lee TH, Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem 2002; 277:20965-73.
62. Murray MM, Mullan PB, Harkin DP. Role played by BRCA1 in transcriptional regulation in response to therapy. Biochem Soc Trans 2007; 35:1342-6.
63. Marsit CJ, Liu M, Nelson HH, et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004; 23:1000-4.
64. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4:1087-100.
65. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
66. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third- generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23:175-83.
67. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62:4899-902.
68. Abbott DW, Thompson ME, Robinson-Benion C, et al. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999; 274:18808-12.
69. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24:4731-7.
70. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-91.
71. Wang L, Wei J, Qian X, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008:97.
72. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13:7413-20.
73. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-16.
74. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non- small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-25.
75. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25:2747-54.
76. Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20:6597-606.
77. Egawa C, Miyoshi Y, Takamura Y, et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001; 95:255-9.
78. Font A, Tarón M, Pérez-Roca L, et al. BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy. J Clin Oncol 2008; 26(15 suppl):255s (Abstract 5021).
79. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008; 108:289-96.
80. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007; 2:e1129.
81. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453-61.
82. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-60.
83. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-97.
84. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719-27.
85. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non- small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26:173-82.
86. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552-9.
87. Strauss GM HJ, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006; 24(18 suppl):365s (Abstract 7007).
88. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356:11-20.
89. Tsao MS, Zhu C, Ding K, et al. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. J Clin Oncol 2008; 26(15 suppl):399s (Abstract 7510).
90. Skrzypski M, Jassem E, Benlloch S, et al. Validation of 5- and 3-gene expression signatures for predicting outcome in non-small cell lung cancer (NSCLC) patients (p). J Clin Oncol 2008; 26(15 suppl):405s (Abstract 7532).
91. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355:570-80.
92. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006; 3:e467.
93. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25:5240-7.
94. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91.
95. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-8.
96. Suehisa H, Toyooka S, Hotta K, et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 2007; 25:3952-7.
97. Le Chevalier T, Dunant A, Arriagada R, et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl):398s (Abstract 7507).
98. Deeb KK, Michalowska AM, Yoon CY, et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007; 67:8065-80.
99. Seery LT, Knowlden JM, Gee JM, et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 1999; 84:258-62.
100. Shen H, Spitz MR, Qiao Y, et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. Int J Cancer 2003; 107:84-8.
101. Fracasso ME, Doria D, Franceschetti P, et al. DNA damage and repair capacity by comet assay in lymphocytes of white-collar active smokers and passive smokers (non- and ex-smokers) at workplace. Toxicol Lett 2006; 167:131-41.
102. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med 2007; 356:2538-40; author reply 40-1.
103. Zhou SF. ERCC1 and non-small-cell lung cancer. N Engl J Med 2007; 356:2540; author reply 41.
104. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006; 355:1054-5.
105. Cobo M, Massuti B, Morán T, et al. Spanish Customized Adjuvant Trial (SCAT) based on BRCA1 mRNA levels. J Clin Oncol 2008; 26(15 suppl):405s (Abstract 7533).